Study to find Effects of Chandraprabha Vati(Ayurvedic Medicine) in Polycystic Ovarian Syndrome Characterised by Small cysts in ovary with irregular,Scanty menses and excess/unwanted hairs on Face,Thighs,Abdomen etc.

â??Randomized controlled clinical trial to study the efficacy OF Chandraprabha vati in PCOS.â??

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/11/028824

Enrollment

140

Registered

2020-11-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Chandraprabha Vati: 500 mg 1 BD with Luke warm water.Just before food.Orally For 6 months. Control Intervention1: Metformin Hydrochoride inthe Form of Tablet.: 500 mg 1 TDS (500 mg 1 OD

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of age group 19-35 years. 2.Diagnosed cases of PCOS (Rotterdam Criteria) Any 2/3 a)Hyperandrogenism (Clinical or Biochemical) b)Oligomenorrhea (Menstrual cycle > 35days)/ Secondary Amenorrhea (Menstrual cycle > 90 days but c) USG findingsâ?? PCO features on USG i.e. Peripherally arranged Antral Follicle Count >12 with thickened stroma in Ovaries And OR Ovarian Volume >10 cm3 in Unilateral or Bilateral ovaries. 3.Both Unmarried and Married patients of PCOS.

Exclusion criteria

Exclusion criteria: 1.Patients of age group 35 yrs. 2.Patients showing signs and symptoms other than PCOS. 3.Patients having any other disease causing Oligomenorrhea & Anovulation excluding PCOS on above criteria i.e.Hypogonadotrophic Hypogonadism, Premature Ovarian Failure. 4.Patients suffering from a) Congenital Adrenal Hyperplasia b) Severe Insulin resistance(Insulin dependant Diabetes Mellitus) c)Androgen secreting Ovarian & Adrenal tumors d)Thyroid abnormalities e) Cushingâ??s syndrome f)Cardiac disease g) Hyperprolactenemia 5.Patients with any organic lesions of Reproductive Tract like TB, Ca, Congenital anomalies, any other pelvic pathologies. 6.A current or previous (within 3 months) use of OC Pills, Glucocorticoids, Antiandrogens, Antidiabetics, Antiobesity drugs or any Hormonal Therapy.

Design outcomes

Primary

Measure	Time frame
1.Menstrual History For Interval between 2 cycles. 2.modified Ferriman Gallwey Score for HirsutismTimepoint: At Enrollment and After 6 months	—

Secondary

Measure	Time frame
BMI IN KG/M2 Sr.Testesterone Sr.Insulin (F) BSL(F) USG (Pelvis)TAS OR TVS 1)PCOS Pattern 2)Ovarian volume Timepoint: At Enrollment and After 6 months	—

Countries

India

Contacts

Public ContactNiranjan Ashok Dumbare

CSMSS Ayurved Mahavidyalay Aurangabad.

dr.jayashrisdeshmukh@gmail.com9325580777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026